Publication|Articles|November 12, 2025

Supplements and Featured Publications

  • Clinical and Economic Considerations for Nivolumab-Based Therapy for Resectable Non–Small Cell Lung Cancer

Clinical and Economic Considerations for Nivolumab-Based Therapy for Resectable Non–Small Cell Lung Cancer

Listen
0:00 / 0:00

This clinical brief is sponsored by Bristol Myers Squibb and is intended for payers, formulary committees, or other similar individuals or entities with knowledge and expertise in the area of health care economic analysis carrying out responsibilities for the selection of drugs for coverage, reimbursement, or other population-based health care management.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo